Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Exp Hematol. 2012 Jun 9;40(10):800–810. doi: 10.1016/j.exphem.2012.06.001

Figure 5.

Figure 5

Epigenetic changes in cells exposed to various combinations of busulfan-melphalan-gemcitabine-SAHA (B±M±G±S). (a) J45.01 cells were continuously exposed for 24 hr to the indicated drugs and total cell extracts were analyzed for early changes in the status of protein poly(ADP-ribosyl)ation by Western blot. G: 0.03 μM gemcitabine; S: 0.6 μM suberoylanilide hydroxamic acid. (b) J45.01 cells were exposed to drugs for 48 hr and the levels of expression and modification status of proteins involved in chromatin remodeling were determined by Western blot. B: 20 μM busulfan; M: 0.7 μM melphalan; G: 0.01 μM gemcitabine; S: 0.6 μM suberoylanilide hydroxamic acid.